Dermatology and Therapy最新文献

{"title":"Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream.","authors":"Timo Buhl, Andrea Bauer, Benjamin D Ehst, Jacob P Thyssen, Julie Hahn-Pedersen, Berith Fredsted Hagen, Eydna D Apol, Tove Agner","doi":"10.1007/s13555-025-01384-4","DOIUrl":"https://doi.org/10.1007/s13555-025-01384-4","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic Hand Eczema (CHE) is a multifactorial, burdensome, inflammatory skin disease, with limited treatment options. In a double-blind dose-ranging phase 2b clinical trial, participants with CHE received delgocitinib cream, a topical pan-Janus kinase (JAK) inhibitor, or cream vehicle (clinical results published elsewhere). The objectives were to analyse patient-reported outcomes (PROs) in participants with mild and moderate to severe CHE at screening, and to investigate the impact on PROs during treatment in participants with moderate to severe CHE.</p><p><strong>Methods: </strong>Firstly, Dermatology Life Quality Index (DLQI), EQ-5D-5L, and Hand Eczema Impact Scale (HEIS) per severity were analysed at screening. Secondly, PROs were analysed in the subset of participants with moderate to severe CHE; participants receiving delgocitinib cream 20 mg/g were compared with participants receiving cream vehicle for 16 weeks.</p><p><strong>Results: </strong>At screening, mean (SD) DLQI, EQ-5D-5L, and HEIS were 8.1 (5.8), 0.788 (0.175), and 1.7 (0.8), respectively for mild CHE (n = 93), and 12.1 (6.9), 0.689 (0.236), and 2.3 (0.9) for participants with moderate to severe CHE (n = 202), respectively. Among the participants with moderate to severe CHE who received delgocitinib (n = 41), the least squares mean [SE] change from baseline to week 16 improved compared to cream vehicle (n = 38) in DLQI (- 7.1 [0.9] vs. - 4.6 [0.9]), EQ-5D-5L (0.228 [0.032] vs. 0.096 [0.034]), and HEIS (- 1.5 [0.2] vs. - 0.8 [0.2]) (P < 0.05).</p><p><strong>Conclusions: </strong>Mild CHE had a moderate effect, whereas moderate to severe CHE had a very large effect on patients' Health-Related Quality of Life at screening. Treatment with delgocitinib cream was associated with considerable improvement in PROs and represents a potentially valuable treatment option.</p><p><strong>Trial registration: </strong>ClinicalTrials. gov identifier NCT03683719.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Tumoral Melanosis: A Case Series of a Rare Clinical Entity.","authors":"Cesare Ariasi, Grazia Linda Artelli, Cristina Zane, Martina Perantoni, Simone Soglia, Giuseppe La Rosa, Vincenzo Maione, Marina Venturini, Claudia Zambelli, Gaetano Licata, Mariateresa Rossi, Mariachiara Arisi","doi":"10.1007/s13555-025-01388-0","DOIUrl":"https://doi.org/10.1007/s13555-025-01388-0","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.","authors":"Kenneth B Gordon, Yayoi Tada, Milan J Anadkat, Siew Eng Choon, Boni Elewski, Jonathan N Barker, Arash Mostaghimi, Kilian Eyerich, Ming Tang, Thomas Haeufel, Christian Thoma, Diamant Thaçi","doi":"10.1007/s13555-025-01372-8","DOIUrl":"https://doi.org/10.1007/s13555-025-01372-8","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Superficial Fungal Infections in WHIM Syndrome.","authors":"Jennifer Strong, Rutha Adhanom, Caleb S Kim, Yoshine Saito, Jasmine C Meltzer, Patrick Hallaert, Sophia Martinez, Abigail Salancy, Heidi H Kong, Edward W Cowen, Leslie Castelo-Soccio, Philip M Murphy, David H McDermott, Isaac Brownell","doi":"10.1007/s13555-025-01396-0","DOIUrl":"https://doi.org/10.1007/s13555-025-01396-0","url":null,"abstract":"<p><strong>Introduction: </strong>WHIM syndrome is a rare autosomal dominant inborn error of immunity caused by gain-of-function mutations in the chemokine receptor CXCR4. Patients with WHIM syndrome frequently suffer from an increased risk for bacterial and viral infections, especially warts due to human papillomavirus. Associations between WHIM syndrome and fungal infections have not been previously identified. The objective of this study was to estimate the prevalence of superficial fungal infections in patients with WHIM syndrome.</p><p><strong>Methods: </strong>This retrospective single-institution cohort study assessed patients with genotype-confirmed WHIM syndrome evaluated between March 2007 and March 2024.</p><p><strong>Results: </strong>Of 45 patients with WHIM syndrome, 18 (40%) were diagnosed with at least one superficial fungal infection. These infections included dermatophytosis (n = 14, 78%), pityriasis versicolor (n = 6, 33%), and pityrosporum folliculitis (n = 1, 6%). No correlation was detected between superficial fungal infection risk and the degree of peripheral neutropenia, lymphopenia, or hypogammaglobulinemia. The median time to resolution of the longest episode of superficial dermatophytosis (skin or hair) was 171.5 (range 53-3650) days, and several patients experienced prolonged courses requiring serial retreatments.</p><p><strong>Conclusions: </strong>These findings suggest that frequent or prolonged superficial fungal infections may be a useful clinical sign to prompt consideration of a WHIM syndrome diagnosis, especially in patients with numerous cutaneous warts or other history to suggest immunodeficiency.</p><p><strong>Trial registration: </strong>Participants were enrolled in a natural history trial registered with ClinicalTrials.gov (NCT00128973).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacts of Topical Treatments and Phototherapy on Stratum Corneum Hydration, Sebum and Elasticity in Vitiligo Skin.","authors":"Yaqing Wen, Issa Ali Issa, Li Lei, Chuhan Fu, Shu Zhou, Keyi Zhang, Jiangfeng Huang, Jing Chen, Qinghai Zeng, Ling Jiang","doi":"10.1007/s13555-025-01398-y","DOIUrl":"https://doi.org/10.1007/s13555-025-01398-y","url":null,"abstract":"<p><strong>Introduction: </strong>Vitiligo is a prevalent depigmentation disorder. Due to the depigmentation and treatments, skin function of patients with vitiligo may be affected, manifested by changes in the stratum corneum (SC) hydration, sebum and elasticity. However, few researchers have paid attention to the skin condition of vitiligo after treatment.</p><p><strong>Methods: </strong>A cross-sectional study was conducted. SC hydration, sebum and elasticity of 154 vitiligo lesions were measured to evaluate skin function after topical treatments and phototherapy and investigate potential influencing factors.</p><p><strong>Results: </strong>Treated vitiligo lesions exhibited significantly lower SC hydration and elasticity compared to normal skin, while sebum levels were notably higher. Combined treatments-specifically, 308-nm excimer laser with topical calcineurin inhibitors (TCI) and either topical corticosteroids (TCS) or compound kaliziran tincture (CKT), as well as 308-nm excimer laser with TCI, TCS and CKT-resulted in reduced SC hydration and elasticity as well as increased sebum levels in lesions. Notably, the 308-nm excimer laser had a greater effect on increasing sebum on lesions.</p><p><strong>Conclusion: </strong>Our findings indicate that skin barrier damage and decreased elasticity occur in patients with vitiligo after topical treatments and phototherapy. This underscores the need for enhanced skin management and appropriate post-treatment skin care for patients with vitiligo.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of PEST Questionnaire Responses in Patients with Psoriasis in Daily Practice: Results from a Single-Center of Psoriasis in the Czech Republic.","authors":"Simona Tivadar, Jan Hugo, Kristína Fuzesiová, Tomáš Doležal, Barbora Turková, Spyridon Gkalpakiotis","doi":"10.1007/s13555-025-01374-6","DOIUrl":"10.1007/s13555-025-01374-6","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriatic arthritis (PsA) affects 10-30% of individuals with psoriasis. Early detection of PsA is crucial to prevent potential irreversible joint damage. The Psoriasis Epidemiology Screening Tool (PEST) has proven to be an effective tool in daily clinical practice, but limited data is available on the analysis of positive responses. Our study aimed to determine the combination of positive responses to individual questions and characterize patients with positive PEST results based on specific anatomical sites of psoriasis, duration of the disease, and epidemiological parameters that could potentially predict PEST positivity.</p><p><strong>Methods: </strong>The PEST questionnaire was randomly administered to patients with psoriasis without psoriatic arthritis attending the outpatient unit for psoriasis treatment. A total of 351 patients completed the PEST questionnaire over a 24-month period. Patients undergoing various types of therapy were included. Each patient completed the PEST questionnaire once, and epidemiological data (such as age, weight, height, body mass index, smoking status, age of disease onset, disease duration, and family history of psoriasis) were collected, as well as types of therapy.</p><p><strong>Results: </strong>We included 242 men and 109 women with an average age of 49.4 years and duration of psoriasis of 23.3 years. A positive PEST questionnaire result was found in 28.5% of patients; 13.1% had a score of 3, 8.0% a score of 4 and 7.4% a score of 5. Nail psoriasis, higher age, and therapy with biological/targeted therapy were associated with PEST positivity. The most frequently observed positive response was nail involvement.</p><p><strong>Conclusion: </strong>The PEST questionnaire is a well-established screening tool for identifying patients at risk of having undiagnosed psoriatic arthritis in daily dermatological practice. Patients with nail involvement, higher age, or treated with modern systemic therapy should be closely monitored, as these factors indicate a higher risk of a positive PEST result and consequently higher risk of having psoriatic arthritis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"819-829"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Hand Eczema (CHE): A Narrative Review.","authors":"Gioele Ghezzi, Costanza Falcidia, Giovanni Paolino, Santo R Mercuri, Alessandra Narcisi, Antonio Costanzo, Mario Valenti","doi":"10.1007/s13555-025-01365-7","DOIUrl":"10.1007/s13555-025-01365-7","url":null,"abstract":"<p><p>Chronic hand eczema (CHE) is a common and challenging skin condition, characterized by persistent hand dermatitis which lasts over 3 months or recurs at least twice a year. This condition is often multifactorial, involving genetic predispositions, environmental factors and triggers, such as irritants and allergens. Studies show a higher incidence in women, though prevalence estimates vary across different age groups. The pathogenesis involves complex immune mechanisms, particularly Th1/Th2 cell responses. Clinically, CHE presents in various forms, with symptoms such as redness, scaling and itching that significantly impact patients' quality of life. Treatment approaches are diverse. While emollients and topical corticosteroids have historically been the mainstay, new systemic therapies like JAK inhibitors and biologics are progressively being used for severe cases. Key molecular targets comprise interleukin (IL)-4 and IL-13, the JAK-STAT pathway, phosphodiesterase 4 (PDE4) and chemoattractant chemokines. Managing CHE effectively remains a challenge because of its chronicity and the variability in individual responses to treatment. However, emerging therapeutic strategies will help clinicians to offer more patient-centred approaches.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"771-795"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).","authors":"Kave Shams, Jennifer Montgomery, Jason Morley, Vaiva Gerasimaviciute, Anouchka Seesaghur, David Neasham, Kathy V Tran, Myriam Cordey, Andrew Taylor","doi":"10.1007/s13555-025-01358-6","DOIUrl":"10.1007/s13555-025-01358-6","url":null,"abstract":"<p><strong>Introduction: </strong>We describe comorbidities and cardiovascular diseases (CVD) risk in patients with psoriasis prescribed apremilast in UK clinical practice. Such real-world data are currently sparse.</p><p><strong>Methods: </strong>This observational, retrospective analysis of British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) included adults with plaque psoriasis first prescribed apremilast between October 2015 and March 2021. We evaluated patient comorbidities, 10-year CVD risk (Framingham risk score), time from psoriasis diagnosis, prior therapy, psoriasis severity and patient-reported quality of life (QoL) at first apremilast prescription or registry enrolment. Patient characteristics were also assessed by CVD risk and Fitzpatrick skin type.</p><p><strong>Results: </strong>Of 265 eligible patients, 47.5% were female; median (Q1, Q3) age at first apremilast prescription was 50 (38, 60) years. The most common comorbidities were hypertension (23.4%), depression (21.5%), psoriatic arthritis (18.1%) and diabetes (15.8%). Median (Q1, Q3) time from psoriasis diagnosis to first apremilast prescription was 19 (11, 30) years; median (Q1, Q3) number of prior psoriasis therapies was 1 (1, 2). Most patients had a Physician Global Assessment score ≥ 3 (moderate/moderate-to-severe/severe disease; 75.5%), psoriasis area severity index ≥ 10 (severe/extensive disease; 82.6%), nail or scalp involvement (52.8% and 75.5%, respectively), and reported moderate or extreme pain/discomfort (57.4%) and/or a Dermatology Life Quality Index (DLQI) > 10 (large/extremely large effect; 59.2%). Among 186 patients without CVD, 63.4% had an intermediate/high 10-year risk of CVD. Patients with darker skin (Fitzpatrick skin types IV-VI) reported worse QoL than those with lighter skin (Fitzpatrick skin types IV-VI, mean [SD] DLQI, 15.7 [7.9]; I-III, 13.9 [7.8]).</p><p><strong>Conclusions: </strong>Our data indicate that patients with plaque psoriasis prescribed apremilast in UK clinical practice have a high comorbidity burden and long-term, moderate-to-severe disease with special-site involvement, uncontrolled by systemic therapy, and which had a large detrimental impact on their QoL. These data highlight the need for timely treatment with appropriate therapy following diagnosis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"903-918"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Narrative Review of Internet-Based Self-Help Tools for Body-Focused Repetitive Behaviors: Recommendations for Clinical Practice.","authors":"Emi M Murase, Sawye Raygani, Jenny E Murase","doi":"10.1007/s13555-025-01380-8","DOIUrl":"10.1007/s13555-025-01380-8","url":null,"abstract":"<p><strong>Introduction: </strong>Body-focused repetitive behaviors (BFRBs), such as skin-picking, hair-pulling, and nail-biting, impair quality of life (QOL). While habit reversal training (HRT) is effective, access is often limited. Internet-based self-help interventions offer an alternative, improving accessibility for patients unable to attend in-person therapy.</p><p><strong>Methods: </strong>We reviewed randomized controlled trials analyzing self-help or internet-based interventions for BFRBs in adults. PubMed searches yielded 1033 studies, 12 of which met the inclusion criteria, focusing on self-guided interventions for various BFRBs.</p><p><strong>Results: </strong>The review found that the \"Free from BFRB\" website was the most studied resource and consistently had high patient satisfaction. Self-guided HRT, decoupling, and decoupling in-sensu consistently reduced symptoms and improved QOL. Decoupling techniques were especially effective for trichotillomania and nail-biting.</p><p><strong>Discussion: </strong>Internet-based self-help interventions, especially self-help HRT, decoupling, and decoupling in-sensu, offer effective and accessible treatment options for managing BFRBs, particularly for those facing barriers to traditional therapy such as stigma, cost, or location. Engagement and frequency of use are important for the efficacy of self-help options, and therapist-guided treatments may offer more personalized, comprehensive care.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"811-818"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.","authors":"April W Armstrong, Matthias Augustin, Jennifer L Beaumont, Tan P Pham, Stacie Hudgens, Kenneth B Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M Kisa, Subhashis Banerjee, Kim A Papp","doi":"10.1007/s13555-024-01317-7","DOIUrl":"10.1007/s13555-024-01317-7","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1037-1044"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}